Argenta's models can provide information on the efficacy, potency, therapeutic index and dosing frequency in human disease. They can also be constructed to provide feedback on activity versus a given target.
The aim of Argenta's models is to reproduce one or more of the features of human chronic respiratory disease which is characterised by pulmonary inflammation, lung remodelling and reduction in lung function. Data generated in these models will allow the selection of mechanisms and compounds with the highest probability of success in treating human disease and prioritise the progression of those compounds into pre-clinical profiling, including safety evaluation.
All models will be profiled with reference agents and an appropriate reference agent will be used in all experiments to ensure the model is working within its predicted range.
In addition to a wide range of established models, Argenta can develop bespoke models for new approaches to the treatment of respiratory diseases such as Chronic Obstructive Pulmonary Disease (COPD) and Asthma. We are continually looking to add to our portfolio of models on offer to our clients. If you have specific requirements then you can contact us for an update on new model development or to discuss development of models tailored to your needs.
For more information on our Respiratory Models please contact us.